These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 37058845)

  • 21. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
    Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066
    [No Abstract]   [Full Text] [Related]  

  • 22. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
    Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
    [No Abstract]   [Full Text] [Related]  

  • 23. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
    Ferment B; Arnulf B
    Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors.
    Prasongtanakij S; Preedagasamzin S; Jittorntrum B; Anurathapan U; Puavilai T; Niparuck P; Chantrathammachart P; Piyajaroenkij T; Uaesoontrachoon K; Uchibori R; Ozawa K; Ohmine K; Hongeng S
    Eur J Haematol; 2024 Feb; 112(2):248-256. PubMed ID: 37222081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
    Lee L; Lim WC; Galas-Filipowicz D; Fung K; Taylor J; Patel D; Akbar Z; Alvarez Mediavilla E; Wawrzyniecka P; Shome D; Reijmers RM; Gregg T; Wood L; Day W; Cerec V; Ferrari M; Thomas S; Cordoba S; Onuoha S; Khokhar N; Peddareddigari V; Al-Hajj M; Cavet J; Zweegman S; Rodriguez-Justo M; Youg K; Pule M; Popat R
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.
    Stock S; Fertig L; Gottschlich A; Dörr J; Märkl F; Majed L; Menkhoff VD; Grünmeier R; Rejeski K; Cordas Dos Santos DM; Theurich S; von Bergwelt-Baildon M; Endres S; Subklewe M; Kobold S
    Cancer Immunol Immunother; 2024 Apr; 73(6):100. PubMed ID: 38630291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
    Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
    Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
    Sun Y; Yang XN; Yang SS; Lyu YZ; Zhang B; Liu KW; Li N; Cui JC; Huang GX; Liu CL; Xu J; Mi JQ; Chen Z; Fan XH; Chen SJ; Chen S
    Signal Transduct Target Ther; 2023 Dec; 8(1):445. PubMed ID: 38062078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.
    Zah E; Nam E; Bhuvan V; Tran U; Ji BY; Gosliner SB; Wang X; Brown CE; Chen YY
    Nat Commun; 2020 May; 11(1):2283. PubMed ID: 32385241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
    Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
    Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
    Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
    J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
    Lu Q; Li H; Wu Z; Zhu Z; Zhang Z; Yang D; Tong A
    J Nanobiotechnology; 2024 May; 22(1):279. PubMed ID: 38783333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy.
    Yang Y; Qin S; Yang M; Wang T; Feng R; Zhang C; Zheng E; Li Q; Xiang P; Ning S; Xu X; Zuo X; Zhang S; Yun X; Zhou X; Wang Y; He L; Shang Y; Sun L; Liu H
    Clin Cancer Res; 2024 Sep; 30(18):4201-4214. PubMed ID: 39024031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
    Lam N; Trinklein ND; Buelow B; Patterson GH; Ojha N; Kochenderfer JN
    Nat Commun; 2020 Jan; 11(1):283. PubMed ID: 31941907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
    García-Guerrero E; Rodríguez-Lobato LG; Sierro-Martínez B; Danhof S; Bates S; Frenz S; Haertle L; Götz R; Sauer M; Rasche L; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Prommersberger SR
    Haematologica; 2023 Feb; 108(2):568-580. PubMed ID: 36722406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma.
    Larson RC; Kann MC; Graham C; Mount CW; Castano AP; Lee WH; Bouffard AA; Takei HN; Almazan AJ; Scarfó I; Berger TR; Schmidts A; Frigault MJ; Gallagher KME; Maus MV
    Nat Commun; 2023 Nov; 14(1):7509. PubMed ID: 37980341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.
    Hanssens H; Meeus F; Gesquiere EL; Puttemans J; De Vlaeminck Y; De Veirman K; Breckpot K; Devoogdt N
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.